



NDA 50-138/S-219

Wyeth-Ayerst Research
Attention: Diane Mitrione
Director, Marketed Products
U.S. Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Mitrione:

Please refer to your supplemental new drug application dated October 16, 1997, received October 17, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Bicillin[®] C-R and Bicillin[®] C-R 900/300 (penicillin G benzathine and penicillin G procaine suspension) Injection.

This supplemental new drug application provides for revisions to **WARNINGS, ADVERSE REACTIONS** and **DOSAGE AND ADMINISTRATION** sections of the label to incorporate important new safety information.

We have completed the review of this supplemental application, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted labeling dated October 16, 1997. Accordingly, this supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 50-138/S-219

Page 2

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

{See appended electronic signature page}

Janice Soreth, M.D.

Director

Division of Anti-Infective Drug Products, HFD-520

Office of Drug Evaluation IV

Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth
3/1/02 11:12:35 AM